RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $543

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $541 to $543.